Mr. Douglas Janzen reports

AEQUUS ANNOUNCES ZIMED PF NOW AVAILABLE IN CANADA

Aequus Pharmaceuticals Inc. has launched Zimed PF, the first preservative-free multidose bimatoprost for glaucoma patients, in Canada.

"This marks a new growth phase for Aequus and the launch of a preservative-free (PF) innovation that brings value to both physicians and patients in a large therapeutic eye category," says Grant Larsen, chief commercial officer for Aequus Pharmaceuticals Inc. Canada. "An exciting product innovation, launched in multiple countries around the world, this product will be available at pharmacies across Canada in the coming weeks."

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals is a growing specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products. Aequus, founded in 2015, has successfully grown multiple products and brands in strategic therapeutic areas including ophthalmology, optometry, transplant and rare disease. Aequus plans to build on its Canadian commercial platform through the application of sales, marketing and expert knowledge of the Canadian marketplace utilizing internal development, acquisition or licences with preferred strategic partners.

We seek Safe Harbor.